The largest of Novartis’ Oncology Access programs – the Glivec International Patient Assistance Program (GIPAP) is a direct-to-patient access program – developed to ensure patients with CML (chronic myeloid leukemia) or GIST (gastrointestinal stromal tumour), two rare cancers, receive treatment.
GIPAP’s aim is to provide breakthrough drug, Glivec, at no cost to patients with certain forms of CML and GIST, who would not otherwise have access to treatment. GIPAP also provides patients with access to support groups, treatment and disease information, education and emotional support to help manage their illness.
Novartis partners with physicians and international health organizations to facilitate access to Glivec via GIPAP. To reach as many CML and GIST patients in need as possible in low and middle income countries, GIPAP partners have established clear roles for the partners and a clear process for the program, engaged local governments and officials, and educated local partners to gain their support and commitment.
The Max Foundation, as Novartis’ main partner in the administration of GIPAP, provides socio-economic evaluation of patients, guides physicians through the patient evaluation process, and provides emotional support, information and referral assistance to patients, their family members and care givers. In addition, we monitor patients to support the highest standard of patient care, collaborate with Novartis to identify and qualify eligible medical centers and physicians worldwide, and protect confidential patient information and data received in the course of program administration.
|Value||USD 1 Billion|